Philips raises 2026 outlook after stronger Q4 and full-year results

Transcript intelligence

What changed

Management reported Q4 order intake growth of 7% and adjusted EBITDA margin of 15.1%, with full-year margin reaching 12.3%. It raised its 2026 outlook to 3–4.5% comparable sales growth and 12.5–13% adjusted EBITDA margin. The event-session share response was positive, while the subsequent drift was negative.

Guidance delta

Raised 2026 outlook to 3–4.5% comparable sales growth and 12.5–13% adjusted EBITDA margin; management cited tariff mitigation.

Key takeaways

• Q4 order intake grew 7%, including double-digit growth in North America across Diagnosis & Treatment and Connected Care.
• Q4 adjusted EBITDA margin expanded to 15.1%; full-year margin was 12.3%, above the prior outlook described in the supplied analysis.
• Management raised 2026 comparable sales growth guidance to 3–4.5% and adjusted EBITDA margin guidance to 12.5–13%.
• Management pointed to new products, productivity savings and North American demand as supports; China demand, tariffs and Respironics-related matters remain important uncertainties.

Management priorities

• Roll out helium-free 3T MRI, Verida spectral CT and LumiGuide AI navigation.
• Execute the EUR 1.5 billion productivity program through 2028.
• Integrate SpectraWAVE capabilities and continue investment in supply-chain resilience and regionalization.
• Expand partnerships with U.S. health systems and cloud-based informatics offerings.